Survival of Patients With Head and Neck Merkel Cell Cancer

• DOI: 10.1001/jamanetworkopen.2023.44127
• Publication Date: 2023-11-20T16:34:27Z
• Authors: Ameeta Lubina Nayak; Arthur Travis Pic...; Megan Delisle; Brittany Dingley; Ranjeeta Mallick; Trevor Hamilton; Heather Stuart; Martha Talbot; Gregory McKinnon; Evan Jost; Eva Thiboutot; Valerie Francescutti; Sal Samman; Alexandra Easson; Angela Schellenberg; Shaila Merchant; Julie La; Kaitlin Vanderbeck; Frances Wright; David Berger-Rich...; Pamela Hebbard; Olivia Hershorn; Rami Younan; Erica Patocskai; Samuel Rodriguez-...; Ari Meguerditichian; Vanina Tchuente; Suzanne Kazandjian; Alex Mathieson; Farisa Hossain; Jessika Hetu; Martin Corsten; Angelina Tohmé; Carolyn Nessim; Stephanie Johnson...
• Keywords: Merkel cell

Importance Merkel cell carcinoma (MCC) is an aggressive cutaneous neuroendocrine carcinoma. Due to its relatively low incidence and limited prospective trials, current recommendations are guided by historical single-institution retrospective studies. Objective To evaluate the overall survival (OS) of patients in Canada with head neck MCC (HNMCC) according American Joint Committee on Cancer 8th edition staging treatment modalities. Design, Setting, Participants A cohort study 400 a diagnosis HNMCC between July 1, 2000, June 31, 2018, was conducted using Pan-Canadian Cell Collaborative, multicenter national registry MCC. Statistical analyses were performed from January December 2022. Main Outcomes Measures The primary outcome 5-year OS. Multivariable analysis Cox proportional hazards regression model identify factors associated survival. Results Between 2000 (234 men [58.5%]; mean [SD] age at diagnosis, 78.4 [10.5] years) malignant neoplasms found face, scalp, neck, ear, eyelid, or lip received HNMCC. At 188 (47.0%) had stage I disease. most common surgery followed radiotherapy (161 [40.3%]), although alone for IV disease (15 23 [52.2%]). Five-year OS 49.8% (95% CI, 40.7%-58.2%), 39.8% 26.2%-53.1%), 36.2% 25.2%-47.4%), 18.5% 3.9%-41.5%) I, II, III, disease, respectively, highest among treated (49.9% [95% 39.9%-59.1%]). On multivariable analysis, greater compared those (hazard ratio [HR], 0.76 0.46-1.25]); however, this not statistically significant. In comparison, who no significantly worse (HR, 1.93 1.26-2.96)]. Conclusions Relevance largest Canada-wide evaluation outcomes, modality Multimodal across all stages.